111 related articles for article (PubMed ID: 1672849)
1. Resistance to doxorubicin in tumor cells in vitro and in vivo after pretreatment with verapamil.
Donenko FV; Efferth T; Mattern J; Moroz LV; Volm M
Chemotherapy; 1991; 37(1):57-61. PubMed ID: 1672849
[TBL] [Abstract][Full Text] [Related]
2. The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo.
Radel S; Bankusli I; Mayhew E; Rustum YM
Cancer Chemother Pharmacol; 1988; 21(1):25-30. PubMed ID: 3342462
[TBL] [Abstract][Full Text] [Related]
3. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
Moroz LV; Donenko FV; Borovkova NB; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1990 Mar; 109(3):290-2. PubMed ID: 2364157
[TBL] [Abstract][Full Text] [Related]
4. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Bollinger P; Loor F
Cancer Res; 1991 Aug; 51(16):4226-33. PubMed ID: 1678313
[TBL] [Abstract][Full Text] [Related]
5. Modulation of in vitro chemosensitivity by extracellular Ca++ in adriamycin sensitive and resistant P388 leukemic cells.
Adwankar MK; Chitnis MP
Neoplasma; 1990; 37(1):31-6. PubMed ID: 2320178
[TBL] [Abstract][Full Text] [Related]
6. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.
Radel S; Fredericks W; Mayhew E; Baker R
Cancer Chemother Pharmacol; 1990; 25(4):241-6. PubMed ID: 1967228
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
Sato W; Fukazawa N; Nakanishi O; Baba M; Suzuki T; Yano O; Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1995; 35(4):271-7. PubMed ID: 7828268
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.
Cuvier C; Roblot-Treupel L; Millot JM; Lizard G; Chevillard S; Manfait M; Couvreur P; Poupon MF
Biochem Pharmacol; 1992 Aug; 44(3):509-17. PubMed ID: 1354963
[TBL] [Abstract][Full Text] [Related]
10. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of doxorubicin-resistant Lewis lung carcinoma variants.
Bruno NA; Carver LA; Slate DL
Cancer Commun; 1990; 2(4):151-8. PubMed ID: 1973357
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin.
Sadasivan R; Morgan R; Fabian C; Stephens R
Cancer Lett; 1991 May; 57(2):165-71. PubMed ID: 1673873
[TBL] [Abstract][Full Text] [Related]
13. Effect of cepharanthine on doxorubicin cytotoxicity in P388 murine leukemia cells in vitro and in vivo.
Fujimura T; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
Res Commun Chem Pathol Pharmacol; 1991 Feb; 71(2):235-8. PubMed ID: 2047569
[TBL] [Abstract][Full Text] [Related]
14. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart.
Rosati A; Decorti G; Klugmann FB; Candussio L; Granzotto M; Melato M; Giraldi T
Anticancer Res; 2000; 20(5B):3403-10. PubMed ID: 11131640
[TBL] [Abstract][Full Text] [Related]
15. Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms.
Efferth T; Volm M
Cancer Lett; 1993 Jul; 70(3):197-202. PubMed ID: 8102593
[TBL] [Abstract][Full Text] [Related]
16. Effects of DMDP, a tiapamil analogue, on adriamycin efflux in adriamycin-resistant and -sensitive P388 cells.
Radel S; Mayhew E; Rustum YM
Anticancer Res; 1987; 7(6):1105-8. PubMed ID: 3442407
[TBL] [Abstract][Full Text] [Related]
17. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.
Sato W; Fukazawa N; Suzuki T; Yusa K; Tsuruo T
Cancer Res; 1991 May; 51(9):2420-4. PubMed ID: 1673087
[TBL] [Abstract][Full Text] [Related]
19. Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells.
Fujimura T; Shibata H; Maekawa I; Furusawa S; Kawauchi H; Sasaki K; Takayanagi Y
Jpn J Pharmacol; 1990 Dec; 54(4):464-7. PubMed ID: 2087009
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase pi gene expression.
Ramachandran C; Yuan ZK; Huang XL; Krishan A
Biochem Pharmacol; 1993 Feb; 45(3):743-51. PubMed ID: 8095141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
